FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer

FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer

60 questions about SCLC with Dr. Gregory Kalemkerian Part 1

Gregory Kalemkerian

100 Influential People in Oncology 2025 - Nominations are Open!

100 Influential People in Oncology 2025

Paving the Way for a Smoke-Free Generation by 2040 - European Cancer Organisation

European Cancer Organisation

Fumiko Ladd Chino: Medical Debt in Patients Receiving Radiation

Fumiko Ladd Chino

iEXPLORE Phase I Trial: Engineered Exosomes with KRASG12D siRNA in Pancreatic Cancer

iEXPLORE

Senator Elissa Slotkin in Response to OncoDaily About Pediatric Cancer Funding

senator elissa slotkin

Patrick Soon-Shiong: New Data with Bioshield Worth Pushing for an RCT in HPV+ HNCC

Patrick Soon-Shiong

OncoCalendar

« All Events

  • This event has passed.

LATAM Course II: Immunotherapy in Lung Cancer by IASLC

Dec 19, 2024 • 4:00 PM - 5:00 PM
LATAM Course II: Immunotherapy in Lung Cancer by IASLC

LATAM Course II: Immunotherapy in Lung Cancer by IASLC will be held at December 19th, 2024.

The exclusive course on the latest updates in lung cancer treatment in LATAM, with a special focus on immunotherapy, will take place in Series II. Renowned thoracic oncology experts from the region will explore the role of immunotherapy in revolutionizing lung cancer care. The discussions will cover crucial topics, including the integration of biomarkers for immunotherapy, optimal management strategies for advanced disease, and addressing challenges like pneumonitis. Participants will have the opportunity to explore how immunotherapy will transform the landscape of lung cancer treatment in LATAM, offering hope for improved patient outcomes.

See the Speakers and Series II LATAM Team Below:

LATAM Course II: Immunotherapy in Lung Cancer by IASLC

Details

Date:
Dec 19, 2024
Time:
4:00 PM - 5:00 PM
Website:
https://www.iaslc.org/node/35047

Organizer

The International Association for the Study of Lung Cancer (IASLC)
Phone
1-855-464-2752
Email
info@iaslc.org